Professional Documents
Culture Documents
realizing cash from debtors but it managed it efficiently while 2010 figure is seen. On the overall impact the company has bought down 3 days in the production process in comparison to the week loss it had till FGSP due to the excessive direct expenses incurred on the final year.
sum-total of RMSP, WIPSP, FGSP and ACP is taken to compute this. The cumulative figures of all these phases for 2008, 2009 & 2010 were 194,199,311 days respectively. It is very evident that in 2009 & 2010 the company had faced problems in production, sales & generation of revenues compared to 2008. This may be due to the effect of the global economic downfall. But the time lag in 2010 was much lesser than it was in 2009 compared to 2008. This also shows a positive sign that the company is recovering well.
which can be a reason Lupin & Cipla covers an extra time period irrespective of the size of the firms & production capacity. It can also be the reason that these two companies got more affected due to the global economic slowdown compared to Ranbaxy as there was less demand in the market at that point. When average collection period is considered which signifies the total time period taken by a company from the point of procuring raw materials to the last realization of cash from the debtors, Ranbaxy took 195, 218 & 221 days in 2008, 2009 & 2010 days respectively whereas Lupin took 193, 199 & 310 days in 2008, 2009 & 2010 respectively. The time period for Cipla was 262, 315 & 298 days in 2008, 2009 & 2010 respectively. From the result we can infer very safely that Ranbaxy maintains a very effective time-period from the point of production to the point of realization of cash from the debtors when compared to Cipla & Lupin. May be Ranbaxy sells goods to debtors who has high credibility & they justifies that by taking less time to pay cash & companies like Lupin & Cipla is not up-to the mark in this aspect Even a company can take some measures in managing the account receivables. If we consider that these three companies do take steps, again Ranbaxy is far better managed compared to the other two. This cumulative result also signifies the GOC for these three companies. The Creditors velocity of Average Payable Period for Ranbaxy is 111, 134 & 180 days in 2008, 2009 & 2010 respectively. Lupins APP in 2008 was 122 days & in 2009 it came down to 78 days. But in 2010, it suddenly increased to 235 days which is not a good sign. Ciplas creditor velocity was 106 days in 2008 but it extended to 111 days in 2009 & again came down to 91 days in 2010. Comparing the three firms its clear that Ranbaxy takes less time to pay its creditors though in 2010 it took some more time compared to its previous records. This is a very important area for the companies as the suppliers do keep an eye on these results. Finally when the NOC is considered, its pretty much visible that Ranbaxys figures came down to 40 days in 2010 from an average of 84 days in 2008 & 2009. Lupins figure for 2008 was 71 days which gradually increased to 188 days in 2009 & again came down to 76 days in 2010 which justifies that the company recovered a lot. Ciplas figure shows that in 2008 it took 155 days but that stretched to 205 days on an average in 2009 & 2010. Actually this is the extra time a company takes to clear its payments to the suppliers. So it does make an impact on the companys credit worthiness. While comparing & analysing the results we can come to a conclusion that Ranbaxy has better credibility while the management of working capital comes into picture though all the companies significantly bought down the NOC in 2010. Although all companies do suffer due to the global economic downfall & there is always a difference in size & production capacity, its really safe to infer that Ranbaxy does have better working capital management in place as compared to Lupin & Cipla.